Bees attack French town, leaving 24 injured
Passersby were stung over a period of about 30 minutes on Sunday morning, according to the Prefecture of Cantal, in south-central France. Firefighters and medical teams were rushed to the scene to treat the victims, while police set up a security perimeter until the bees stopped their attack.
The three people in critical condition were evacuated to a local hospital. Pierre Mathonier, the mayor of Aurillac, told French broadcaster BFM TV on Monday that their condition has improved.
One of them was a 78-year-old person who had to be resuscitated after cardiorespiratory arrest and is now in stable condition, he said. The two others 'are in good health,' he added.
According to the mayor, the incident may have been related to Asian hornets threatening a beehive that had been installed on the roof terrace of a downtown hotel more than a decade ago. He said that this had likely caused the bees to become aggressive.
Mathonier said that the beekeeper has removed the beehive and relocated it outside of the town.
Lt. Col. Michel Cayla, in charge of the local fire services, said that he had never experienced such an attack. He said the victim who was in cardiorespiratory arrest had to be resuscitated in the fire department's ambulance.
'In terms of the number of victims, the panic among the people and the severity of some of the injuries, it was impressive,' he told broadcaster TF1.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Rituximab No Better Than Standard Therapy for EGPA Remission
TOPLINE: Rituximab did not show superiority over conventional therapy in inducing remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). Both treatment groups had similar remission rates at 180 and 360 days, with no significant differences in relapse rates or adverse events. METHODOLOGY: A phase 3, multicenter, randomized, controlled superiority trial was conducted in France to compare rituximab with conventional therapy for EGPA remission induction. A total of 105 adult patients with active EGPA (mean age, 58.4 years; 52.4% women), defined by a Birmingham Vasculitis Activity Score (BVAS, version 3) ≥ 3, were enrolled between December 2016 and October 2019 and randomly assigned to receive either rituximab (n = 52) or conventional therapy on the basis of the five-factor score (n = 53). Patients in the rituximab group received 1 g of rituximab on days 1 and 15, along with glucocorticoids on a tapering schedule; those with a five-factor score ≥ 1 received placebo-cyclophosphamide and placebo-uromitexan. The conventional therapy group received glucocorticoids on a tapering schedule with or without cyclophosphamide on the basis of a five-factor score ≥ 1. The primary endpoint was the proportion of patients who achieved remission, defined as the absence of EGPA disease activity (indicated by a BVAS of 0 at a prednisone dose of ≤ 7.5 mg/d), at 180 days. Secondary endpoints included the duration of remission, glucocorticoid dose, and safety, with follow-up visits scheduled up to 360 days. TAKEAWAY: At 180 days, 63.5% of patients in the rituximab group and 60.4% in the conventional group achieved remission (relative risk, 1.05; P = .75). At 360 days, remission rates were similar between the groups: 59.6% in the rituximab group and 64.2% in the conventional group. The time to remission was a median of 2 weeks in both the groups. Among patients who achieved a BVAS of 0, the mean duration of remission was comparable — 48.5 weeks for rituximab and 49.1 weeks for conventional therapy. No significant differences were observed in relapse rates or serious adverse event rates between the rituximab and conventional therapy groups. Infections and cardiovascular events were the most common serious adverse events. IN PRACTICE: 'On the basis of the results of this trial, the role of rituximab in the therapeutic management of EGPA has been updated,' the authors of the study wrote. 'In most of the study population with nonsevere EGPA, the lack of a clinically meaningful effect of rituximab in addition to the conventional strategy of glucocorticoids alone may appropriately inform clinical decision-making,' they added. SOURCE: The study was led by Benjamin Terrier, MD, PhD, Université Paris Cité in Paris, France. It was published online on July 28, 2025, in Annals of Internal Medicine. LIMITATIONS: The study's design as a superiority trial may not adequately address the equivalence between rituximab and conventional therapy. The limited sample size, due to the rarity of EGPA, affected the precision of subgroup analyses. The focus on remission induction in the vasculitis phase may differ from other studies. DISCLOSURES: The study was funded by research grants from the French Ministry of Health and sponsored by Assistance Publique-Hôpitaux de Paris. Additional disclosures are noted in the original article online. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
an hour ago
- Yahoo
Human Papilloma Virus Testing Market Research Report 2025-2033 Featuring Abbott Laboratories, BioMerieux, Bio-Rad Laboratories, Epigenomics, Siemens Healthineers, Hologic, Qiagen, F. Hoffmann-La Roche
The Human Papillomavirus (HPV) Testing Market is projected to grow from USD 1.52 billion in 2024 to USD 3.62 billion by 2033, at a 10.11% CAGR from 2025. This growth is fueled by increased cervical cancer awareness, robust screening programs, and advancements in diagnostic technologies. HPV, a significant sexually transmitted infection, plays a critical role in cervical and other cancers, highlighting the importance of early detection through testing. Global initiatives, especially in developed nations, have embraced HPV-based screenings, driving demand. However, challenges such as limited access and high technology costs in low-income countries remain. Notable market segments include consumables, immunodiagnostics, and PCR testing. Key regions like the U.S., France, India, and Saudi Arabia see varied growth based on governmental support, awareness, and infrastructure. Human Papilloma Virus Testing Market Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "Human Papilloma Virus Testing Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to Human papillomavirus (HPV) Testing Market was USD 1.52 billion in 2024 and is expected to reach USD 3.62 billion by 2033, with a CAGR of 10.11% from 2025 to 2033. The growth is due to increasing awareness of cervical cancer, increased screening programs, and technological advancements in diagnostic technologies in global healthcare systems. Internationally, the use of HPV testing is increasing with growing awareness regarding prevention of cervical cancer, government-sponsored screening programs, and WHO's initiative to eliminate cervical cancer as a public health issue. Developed countries have embraced HPV-based screening on a large scale, and developing nations are also adopting it, with the support of global health programs. Its high sensitivity and long-term risk prediction make it a method of choice in contemporary gynecological Driver in the Human Papilloma Virus (HPV) Testing Market Increasing Awareness and Government Screening ProgramsInternational awareness programs and country-level screening programs have increased demand for HPV testing to a large extent. Governments in developed and emerging economies are adopting routine cervical cancer screening guidelines for women aged 30 and older. WHO organizations advocate for HPV testing as a key tool for early detection of cancer. Greater awareness of HPV-associated cancers and immunization also reinforces demand. These efforts account for early diagnosis, prompt intervention, and overall reduction in HPV-associated disease burden, thus driving the market forward. SEP 2024, The United States, Australia, India, and Japan are rolling out a key initiative to fight cervical cancer across the Indo-Pacific, a preventable disease which is a significant health crisis in the region. This initiative is part of larger announcements made during the Quad Leaders Breakthroughs in HPV TestingInnovation in diagnostic methods - like PCR, next-generation sequencing, and self-sampling kits - has revolutionized HPV testing by enhancing accuracy, accessibility, and convenience. Automated platforms, multiplex assays, and liquid-based cytology enable quicker turnaround times and large-scale screening. These technologies are particularly precious in resource-poor settings and enable wider adoption in public health systems. Ongoing R&D spending by diagnostic firms serves to improve test sensitivity and affordability, fueling additional market growth. June 2023, The WHO has prequalified a fourth test for human papillomavirus (HPV). Although most HPV infections will clear on their own, a few of the higher-risk types can cause cervical cancer, so HPV testing is important for cervical cancer Prevalence of HPV-Associated Cancers Growing global incidence of HPV-related cancers, particularly cervical cancer, is a strong market driver. Cervical cancer is the fourth leading female cancer in the world according to the WHO, and the overwhelming majority of cases are caused by high-risk HPV types. Growing cases of cancer have driven the need for early detection strategies, putting HPV testing at the center of preventive medicine. As healthcare professionals and patients strive for surefire diagnostic measures, HPV testing is also becoming a necessity in women's health care. An estimated 47,984 new cases of cancer occur each year in the United States in areas of the body where human papillomavirus (HPV) commonly in the Human Papilloma Virus (HPV) Testing Market Limited Access in Low-Income CountriesIn spite of worldwide awareness, HPV testing is not readily available in low- and middle-income countries because of a lack of healthcare infrastructure and resources. There are few laboratory facilities, skilled professionals, and regular screening programs in most areas. Cultural taboo and sexual stigma also discourage HPV testing participation. This inequality avoids early diagnosis and enhances the risk of cervical cancer at advanced stages. It is essential to overcome these barriers using cost-effective point-of-care diagnostics and education initiatives for equitable market Cost of Sophisticated HPV Testing TechnologiesThe price of advanced HPV testing technologies, including PCR-based platforms and DNA sequencing, can be out of reach for healthcare systems and some patients. As developed nations implement these technologies into regular screening, the affordability gap restricts accessibility in resource-scarce settings. In addition, maintenance costs, quality assurance, and specialized staff requirements contribute to higher operating costs for clinics and laboratories. This cost factor hinders mass screening activities, particularly in developing countries. Key Players Analyzed: Overview, Key Persons, Recent Development & Strategies, Financial Insights Abbott Laboratories BioMerieux SA Bio-Rad Laboratories, Inc. Epigenomics AG Siemens Healthineers AG Hologic Inc Qiagen NV F. Hoffmann-La Roche Ltd Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $1.52 Billion Forecasted Market Value (USD) by 2033 $3.62 Billion Compound Annual Growth Rate 10.1% Regions Covered Global Key Topics Covered: 1. Introduction2. Research Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Human Papilloma Virus Testing Market5.1 Historical Market Trends5.2 Market Forecast6. Human Papilloma Virus Testing Market Share Analysis6.1 By Application6.2 By Product6.3 By Technology6.4 By End Use6.5 By Countries7. Application7.1 Cervical Cancer Screening7.2 Vaginal Cancer Screening8. Product8.1 Consumables8.2 Instruments8.3 Services9. Technology9.1 Polymerase chain reaction (PCR)9.2 Liquid-based cytology9.3 Immunodiagnostics9.4 Hybrid Capture9.5 Others10. End Use10.1 Hospitals & Clinics10.2 Laboratories10.3 Others11. Countries11.1 North America11.1.1 United States11.1.2 Canada11.2 Europe11.2.1 France11.2.2 Germany11.2.3 Italy11.2.4 Spain11.2.5 United Kingdom11.2.6 Belgium11.2.7 Netherlands11.2.8 Turkey11.3 Asia-Pacific11.3.1 China11.3.2 Japan11.3.3 India11.3.4 South Korea11.3.5 Thailand11.3.6 Malaysia11.3.7 Indonesia11.3.8 Australia11.3.9 New Zealand11.4 Latin America11.4.1 Brazil11.4.2 Mexico11.4.3 Argentina11.5 Middle East & Africa11.5.1 Saudi Arabia11.5.2 UAE11.5.3 South Africa12. Porter's Five Forces Analysis12.1 Bargaining Power of Buyers12.2 Bargaining Power of Suppliers12.3 Degree of Rivalry12.4 Threat of New Entrants12.5 Threat of Substitutes13. SWOT Analysis13.1 Strength13.2 Weakness13.3 Opportunity13.4 Threat 14. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Human Papilloma Virus Testing Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 hours ago
- Yahoo
Human Papilloma Virus Testing Market Research Report 2025-2033 Featuring Abbott Laboratories, BioMerieux, Bio-Rad Laboratories, Epigenomics, Siemens Healthineers, Hologic, Qiagen, F. Hoffmann-La Roche
The Human Papillomavirus (HPV) Testing Market is projected to grow from USD 1.52 billion in 2024 to USD 3.62 billion by 2033, at a 10.11% CAGR from 2025. This growth is fueled by increased cervical cancer awareness, robust screening programs, and advancements in diagnostic technologies. HPV, a significant sexually transmitted infection, plays a critical role in cervical and other cancers, highlighting the importance of early detection through testing. Global initiatives, especially in developed nations, have embraced HPV-based screenings, driving demand. However, challenges such as limited access and high technology costs in low-income countries remain. Notable market segments include consumables, immunodiagnostics, and PCR testing. Key regions like the U.S., France, India, and Saudi Arabia see varied growth based on governmental support, awareness, and infrastructure. Human Papilloma Virus Testing Market Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "Human Papilloma Virus Testing Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to Human papillomavirus (HPV) Testing Market was USD 1.52 billion in 2024 and is expected to reach USD 3.62 billion by 2033, with a CAGR of 10.11% from 2025 to 2033. The growth is due to increasing awareness of cervical cancer, increased screening programs, and technological advancements in diagnostic technologies in global healthcare systems. Internationally, the use of HPV testing is increasing with growing awareness regarding prevention of cervical cancer, government-sponsored screening programs, and WHO's initiative to eliminate cervical cancer as a public health issue. Developed countries have embraced HPV-based screening on a large scale, and developing nations are also adopting it, with the support of global health programs. Its high sensitivity and long-term risk prediction make it a method of choice in contemporary gynecological Driver in the Human Papilloma Virus (HPV) Testing Market Increasing Awareness and Government Screening ProgramsInternational awareness programs and country-level screening programs have increased demand for HPV testing to a large extent. Governments in developed and emerging economies are adopting routine cervical cancer screening guidelines for women aged 30 and older. WHO organizations advocate for HPV testing as a key tool for early detection of cancer. Greater awareness of HPV-associated cancers and immunization also reinforces demand. These efforts account for early diagnosis, prompt intervention, and overall reduction in HPV-associated disease burden, thus driving the market forward. SEP 2024, The United States, Australia, India, and Japan are rolling out a key initiative to fight cervical cancer across the Indo-Pacific, a preventable disease which is a significant health crisis in the region. This initiative is part of larger announcements made during the Quad Leaders Breakthroughs in HPV TestingInnovation in diagnostic methods - like PCR, next-generation sequencing, and self-sampling kits - has revolutionized HPV testing by enhancing accuracy, accessibility, and convenience. Automated platforms, multiplex assays, and liquid-based cytology enable quicker turnaround times and large-scale screening. These technologies are particularly precious in resource-poor settings and enable wider adoption in public health systems. Ongoing R&D spending by diagnostic firms serves to improve test sensitivity and affordability, fueling additional market growth. June 2023, The WHO has prequalified a fourth test for human papillomavirus (HPV). Although most HPV infections will clear on their own, a few of the higher-risk types can cause cervical cancer, so HPV testing is important for cervical cancer Prevalence of HPV-Associated Cancers Growing global incidence of HPV-related cancers, particularly cervical cancer, is a strong market driver. Cervical cancer is the fourth leading female cancer in the world according to the WHO, and the overwhelming majority of cases are caused by high-risk HPV types. Growing cases of cancer have driven the need for early detection strategies, putting HPV testing at the center of preventive medicine. As healthcare professionals and patients strive for surefire diagnostic measures, HPV testing is also becoming a necessity in women's health care. An estimated 47,984 new cases of cancer occur each year in the United States in areas of the body where human papillomavirus (HPV) commonly in the Human Papilloma Virus (HPV) Testing Market Limited Access in Low-Income CountriesIn spite of worldwide awareness, HPV testing is not readily available in low- and middle-income countries because of a lack of healthcare infrastructure and resources. There are few laboratory facilities, skilled professionals, and regular screening programs in most areas. Cultural taboo and sexual stigma also discourage HPV testing participation. This inequality avoids early diagnosis and enhances the risk of cervical cancer at advanced stages. It is essential to overcome these barriers using cost-effective point-of-care diagnostics and education initiatives for equitable market Cost of Sophisticated HPV Testing TechnologiesThe price of advanced HPV testing technologies, including PCR-based platforms and DNA sequencing, can be out of reach for healthcare systems and some patients. As developed nations implement these technologies into regular screening, the affordability gap restricts accessibility in resource-scarce settings. In addition, maintenance costs, quality assurance, and specialized staff requirements contribute to higher operating costs for clinics and laboratories. This cost factor hinders mass screening activities, particularly in developing countries. Key Players Analyzed: Overview, Key Persons, Recent Development & Strategies, Financial Insights Abbott Laboratories BioMerieux SA Bio-Rad Laboratories, Inc. Epigenomics AG Siemens Healthineers AG Hologic Inc Qiagen NV F. Hoffmann-La Roche Ltd Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $1.52 Billion Forecasted Market Value (USD) by 2033 $3.62 Billion Compound Annual Growth Rate 10.1% Regions Covered Global Key Topics Covered: 1. Introduction2. Research Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Human Papilloma Virus Testing Market5.1 Historical Market Trends5.2 Market Forecast6. Human Papilloma Virus Testing Market Share Analysis6.1 By Application6.2 By Product6.3 By Technology6.4 By End Use6.5 By Countries7. Application7.1 Cervical Cancer Screening7.2 Vaginal Cancer Screening8. Product8.1 Consumables8.2 Instruments8.3 Services9. Technology9.1 Polymerase chain reaction (PCR)9.2 Liquid-based cytology9.3 Immunodiagnostics9.4 Hybrid Capture9.5 Others10. End Use10.1 Hospitals & Clinics10.2 Laboratories10.3 Others11. Countries11.1 North America11.1.1 United States11.1.2 Canada11.2 Europe11.2.1 France11.2.2 Germany11.2.3 Italy11.2.4 Spain11.2.5 United Kingdom11.2.6 Belgium11.2.7 Netherlands11.2.8 Turkey11.3 Asia-Pacific11.3.1 China11.3.2 Japan11.3.3 India11.3.4 South Korea11.3.5 Thailand11.3.6 Malaysia11.3.7 Indonesia11.3.8 Australia11.3.9 New Zealand11.4 Latin America11.4.1 Brazil11.4.2 Mexico11.4.3 Argentina11.5 Middle East & Africa11.5.1 Saudi Arabia11.5.2 UAE11.5.3 South Africa12. Porter's Five Forces Analysis12.1 Bargaining Power of Buyers12.2 Bargaining Power of Suppliers12.3 Degree of Rivalry12.4 Threat of New Entrants12.5 Threat of Substitutes13. SWOT Analysis13.1 Strength13.2 Weakness13.3 Opportunity13.4 Threat 14. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Human Papilloma Virus Testing Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Melden Sie sich an, um Ihr Portfolio aufzurufen.
